RO-9187 - HCV 抑制劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERO-9187Cat. No.: HY-10870CAS No.: 876708-03-1分式: CHNO分量: 284.23作靶點: HCV作通路: Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 7.14 mg/mL (25.12 mM; Need ultrasonic)Mass Solvent1

2、mg 5 mg 10 mg Concentration制備儲備液1 mM 3.5183 mL 17.5914 mL 35.1828 mL5 mM 0.7037 mL 3.5183 mL 7.0366 mL10 mM 0.3518 mL 1.7591 mL 3.5183 mL請根據(jù)產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 RO-9187效的HCV病毒復制抑制劑，IC50值為171 nM。IC50 & Target IC50: 171 nM (HCV) 1體外研究RO-9187 is excellent subs

3、trates for deoxycytidine kinase and is phosphorylated with efficiencies up to 3-foldhigher than deoxycytidine. RO-9187 inhibits RNA synthesis by HCV polymerases from either HCV genotypes1a and 1b or containing S96T or S282T point mutations with similar potencies, suggesting no cross-1/2 Master of Sm

4、all Molecules 您邊的抑制劑師www.MedChemEresistance with either R1479 (4-azidocytidine) or 2-C-methyl nucleosides. The formation of RO-9187-TPincreased in a time- and dose-dependent manner. The maximal triphosphate concentration at 24 h is 87pmol/106 cells with half-maximal triphosphate formation achieved a

5、t 12 M RO-9187 1.體內研究 Plasma exposures of RO-9187 in rats increase in a dose-dependent manner between 10 and 2000 mg/kgafter oral dosing. Plasma concentrations of 1.4 and 26 M (390 and 7454 ng/mL) are achieved in rats anddogs at the 10 mg/kg dose level, respectively. Plasma concentrations up to 57 M

6、 are achieved in rats dosedwith 2000 mg/kg/day 1.PROTOCOLAnimal Rats: A 2-week oral range finding toxicity study is performed with RO-9187 and ribavirin in Hanover-WistarAdministration 1 rats. Five male and five female rats in each of five treatment groups are administered once daily doses ofvehicle

7、, 200, 600, or 2000 mg/kg RO-9187 or 200 mg/kg ribavirin by oral gavage for 14 days 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發(fā)表的科研獻 J Infect Dis. 2016 Sep 1;214(5):707-11. J Virol. 2017 Oct 13;91(21). pii: e01028-17. Antivir Res. 2019 Jul.

8、 Antiviral Res. 2016 Sep;133:119-29.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Klumpp K, et al. 2-deoxy-4-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2-alpha-hydroxyl groups. J Biol Chem. 2008 Jan 25;283(4):2167-75.McePdfHeightCaution: Product has not been fully validated for medical applications